MRM Health Announces First Patient Dosed with Next Generation Live Microbiome Consortia Therapeutic MH002 in Phase 1b/2a Study in Patients with Ulcerative Colitis
GHENT, Belgium, Dec. 08, 2021 (GLOBE NEWSWIRE) — MRM Health, a clinical-stage biopharmaceutical company developing next-generation live microbiome consortia therapeutics,